Skip to main content
Daniel Landsburg, MD, Oncology, Philadelphia, PA, Hospital of the University of Pennsylvania

DanielJLandsburgMD

Oncology • Philadelphia, PA

Physician

Join to view full profile

Dr. Landsburg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Landsburg's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2011 - 2014
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2008 - 2011
  • Lewis Katz School of Medicine at Temple University
    Lewis Katz School of Medicine at Temple UniversityClass of 2008

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2008 - 2024
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas into Effective New Therapies  
    Daniel J Landsburg, Brad S Kahl, Clinical Lymphoma, Myeloma, & Leukemia
  • Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma  
    Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

  • A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0410
    Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
    Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
    Daniel J. Landsburg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Retrospective Analysis Identifies Need for Better Classification of Rare Lymphoma
    Retrospective Analysis Identifies Need for Better Classification of Rare LymphomaDecember 4th, 2019
  • CAR T Studies Highlight Abramson Cancer Center Research at ASH Annual Meeting
    CAR T Studies Highlight Abramson Cancer Center Research at ASH Annual MeetingNovember 26th, 2018
  • Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in Remission
    Stem-Cell Transplant Benefit Limited for Double-Hit Lymphoma Patients in RemissionMay 22nd, 2017
  • Join now to see all

Hospital Affiliations

Dr. Daniel Landsburg, Dr. Daniel Landsburg, MD, Dr. D Landsburg, Dr. Daniel J Landsburg